AbbVie Inc (ABBV)vsRepro Med Systems Inc (KRMD)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
KRMD
Repro Med Systems Inc
$3.16
+0.32%
HEALTHCARE · Cap: $147.90M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 142639% more annual revenue ($64.39B vs $45.11M). ABBV leads profitability with a 9.8% profit margin vs -4.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
KRMD
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Intrinsic value data unavailable for KRMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
18.2% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 8.1x book value
Smaller company, higher risk/reward
Weak financial health signals
ROE of -13.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : KRMD
The strongest argument for KRMD centers on Debt/Equity, Revenue Growth. Revenue growth of 18.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : KRMD
The primary concerns for KRMD are Price/Book, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while KRMD is a growth play — different risk/reward profiles.
KRMD carries more volatility with a beta of 0.45 — expect wider price swings.
KRMD is growing revenue faster at 18.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 26/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Repro Med Systems Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company is headquartered in Chester, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?